{"id":7680,"date":"2026-05-18T15:52:00","date_gmt":"2026-05-18T13:52:00","guid":{"rendered":"https:\/\/hermix.com\/?p=7680"},"modified":"2026-05-18T15:52:00","modified_gmt":"2026-05-18T13:52:00","slug":"appel-doffres-public-du-mid-south-essex-nhs-foundation-trust-pour-des-medicaments-de-therapie-anticancereuse-systemique-prepares-de-maniere-aseptique","status":"publish","type":"post","link":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/","title":{"rendered":"Appel d&#039;offres public du Mid South Essex NHS Foundation Trust pour des m\u00e9dicaments de th\u00e9rapie anticanc\u00e9reuse syst\u00e9miques pr\u00e9par\u00e9s de mani\u00e8re aseptique"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Consulter l&#039;int\u00e9gralit\u00e9 des donn\u00e9es de l&#039;appel d&#039;offres\u00a0: <a href=\"https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026\">https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Un accord-cadre d&#039;une valeur d&#039;un peu plus d&#039;un milliard de livres sterling sur 96 mois, couvrant les m\u00e9dicaments anticanc\u00e9reux \u00e0 doses modulables, sp\u00e9cifiques au patient et CIVAS, ainsi que les services de gestion des stocks, structur\u00e9 pour desservir les sites du NHS dans le sud-est, les Midlands de l&#039;Est et les Midlands de l&#039;Ouest de l&#039;Angleterre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le Mid South Essex NHS Foundation Trust a publi\u00e9 un avis de march\u00e9 sur le service britannique Find a Tender Service pour un accord-cadre portant sur la fourniture de m\u00e9dicaments anticanc\u00e9reux syst\u00e9miques pr\u00e9par\u00e9s de mani\u00e8re aseptique. La valeur totale estim\u00e9e s&#039;\u00e9l\u00e8ve \u00e0 1\u00a0003\u00a0992\u00a0346,03 \u20ac sur une dur\u00e9e de 96 mois, r\u00e9partie en quatre lots. Le descriptif succinct indique que l&#039;accord-cadre couvre la fabrication par lots de m\u00e9dicaments pr\u00eats \u00e0 l&#039;emploi, la fabrication et la fourniture personnalis\u00e9es, le service centralis\u00e9 de pr\u00e9paration des additifs intraveineux (CIVAS) et la gestion des stocks. Deux avis d&#039;information pr\u00e9alable ont \u00e9t\u00e9 publi\u00e9s en mai et ao\u00fbt 2025 avant la parution de l&#039;avis de march\u00e9 officiel en avril 2026, ce qui indique une p\u00e9riode de consultation du march\u00e9 prolong\u00e9e.<\/p>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\">Aper\u00e7u des opportunit\u00e9s<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autorit\u00e9 contractante :<\/strong> Fondation NHS Mid South Essex<\/li>\n\n\n\n<li><strong>Type d&#039;acheteur : <\/strong>Minist\u00e8re ou toute autre autorit\u00e9 nationale ou f\u00e9d\u00e9rale<\/li>\n\n\n\n<li><strong>Activit\u00e9 principale :<\/strong> Inconnu (comme indiqu\u00e9 dans l&#039;avis)<\/li>\n\n\n\n<li><strong>Num\u00e9ro de r\u00e9f\u00e9rence :<\/strong> PR-2264<\/li>\n\n\n\n<li><strong>ID du document\u00a0: <\/strong>ukfts_033144-2026<\/li>\n\n\n\n<li><strong>Titre de l&#039;appel d&#039;offres : <\/strong>M\u00e9dicaments anticanc\u00e9reux syst\u00e9miques pr\u00e9par\u00e9s de mani\u00e8re aseptique<\/li>\n\n\n\n<li><strong>Contact :<\/strong> Service client\u00e8le, customercare@htepg.com, 01268 524900<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">\u00c9tendue des travaux, telle qu&#039;indiqu\u00e9e dans l&#039;avis\u00a0:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fourniture d&#039;une gamme de m\u00e9dicaments anticanc\u00e9reux syst\u00e9miques pr\u00e9par\u00e9s de mani\u00e8re aseptique et fabriqu\u00e9s par lots, pr\u00e9sent\u00e9s sous forme pr\u00eate \u00e0 l&#039;emploi et aux doses convenues.<\/li>\n\n\n\n<li>Fabrication et fourniture de m\u00e9dicaments anticanc\u00e9reux syst\u00e9miques sp\u00e9cifiques au patient<\/li>\n\n\n\n<li>Exigences du CIVAS (Service central d&#039;administration intraveineuse d&#039;additifs)<\/li>\n\n\n\n<li>Gestion des stocks et approvisionnement en traitements anticanc\u00e9reux syst\u00e9miques compos\u00e9s<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Structure des lots (valeur de cadre partag\u00e9e entre tous les lots)\u00a0:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lot 1 :<\/strong> M\u00e9dicaments de th\u00e9rapie anticanc\u00e9reuse syst\u00e9mique \u00e0 doses \u00e9chelonn\u00e9es (1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac)\u00a0: M\u00e9dicaments SACT pr\u00e9par\u00e9s de mani\u00e8re aseptique et \u00e0 doses \u00e9chelonn\u00e9es pour les patients adultes et p\u00e9diatriques, fournis en lots ou en unit\u00e9s individuelles, conform\u00e9ment aux tableaux nationaux de doses \u00e9chelonn\u00e9es.<\/li>\n\n\n\n<li><strong>Lot 2 : <\/strong>M\u00e9dicaments anticanc\u00e9reux syst\u00e9miques personnalis\u00e9s (1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac)\u00a0: M\u00e9dicaments anticanc\u00e9reux pr\u00e9par\u00e9s de mani\u00e8re aseptique et personnalis\u00e9s pour les patients adultes et p\u00e9diatriques<\/li>\n\n\n\n<li><strong>Lot 3 :<\/strong> CIVAS \/ Service central d&#039;additifs intraveineux (1\u00a0003\u00a0992\u00a0346,03 \u20ac)\u00a0: M\u00e9dicaments utilis\u00e9s dans les CIVA, y compris toute pr\u00e9paration de m\u00e9dicament manipul\u00e9e de mani\u00e8re aseptique pour cr\u00e9er un m\u00e9dicament injectable pr\u00eat \u00e0 l&#039;emploi<\/li>\n\n\n\n<li><strong>Lot 4 :<\/strong> Gestion des stocks et approvisionnement de m\u00e9dicaments SACT compos\u00e9s (1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac)\u00a0: Stockage, entreposage, gestion des stocks et approvisionnement de lots de m\u00e9dicaments SACT pour une livraison le lendemain ou \u00e0 date convenue.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Remarque\u00a0: Les valeurs des lots indiqu\u00e9s sont identiques et repr\u00e9sentent le montant total de l\u2019accord-cadre commun de 1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac, et non quatre montants de contrats distincts. La valeur totale estim\u00e9e de l\u2019accord-cadre est de 1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lieu de repr\u00e9sentation (tous les lots) : <\/strong>Sud-Est (Angleterre), Midlands de l&#039;Est (Angleterre), Midlands de l&#039;Ouest (Angleterre)<\/li>\n\n\n\n<li><strong>Type de contrat :<\/strong> Fournitures<\/li>\n\n\n\n<li><strong>Dur\u00e9e du contrat : <\/strong>96 mois<\/li>\n\n\n\n<li><strong>Proc\u00e9dure : <\/strong>Ouvrir<\/li>\n\n\n\n<li><strong>Crit\u00e8res d&#039;attribution (tous lots)\u00a0: <\/strong>Valeur technique et sociale (qualit\u00e9)\u00a0: 65%\u00a0; co\u00fbt\u00a0: 35%<\/li>\n\n\n\n<li><strong>Valeur totale estim\u00e9e :<\/strong> \u20ac1,003,992,346.03<\/li>\n\n\n\n<li><strong>Date de publication : <\/strong>13 avril 2026<\/li>\n\n\n\n<li><strong>Date limite de soumission\u00a0: <\/strong>11 mai 2026<\/li>\n\n\n\n<li><strong>Date d&#039;ouverture des soumissions : <\/strong>11 mai 2026<\/li>\n\n\n\n<li><strong>Financement de l&#039;UE : <\/strong>Non<\/li>\n\n\n\n<li><strong>Source <\/strong>Service de recherche d&#039;appels d&#039;offres au Royaume-Uni<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Avis connexes\u00a0:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ukfts_024556-2025\u00a0: Avis d\u2019information pr\u00e9alable, publi\u00e9 le 22\u00a0mai\u00a02025, M\u00e9dicaments \u00e0 doses group\u00e9es pr\u00e9par\u00e9s de mani\u00e8re aseptique<\/li>\n\n\n\n<li>ukfts_048018-2025\u00a0: Avis d\u2019information pr\u00e9alable, publi\u00e9 le 12 ao\u00fbt 2025, M\u00e9dicaments \u00e0 doses conditionn\u00e9es de mani\u00e8re aseptique, d\u2019une valeur de 789\u00a0239\u00a0286,08\u00a0\u20ac<\/li>\n\n\n\n<li>ukfts_033144-2026\u00a0: Avis de march\u00e9, publi\u00e9 le 13 avril 2026, d\u2019une valeur de 1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Pr\u00eat \u00e0 qualifier des appels d'offres de ce type plus rapidement ?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Cr\u00e9ez votre compte Hermix gratuit sur <a href=\"https:\/\/hermix.com\/fr\/sinscrire\/\">https:\/\/hermix.com\/sign-up\/<\/a> et acc\u00e9dez \u00e0 une analyse des appels d'offres propuls\u00e9e par l'IA, \u00e0 une veille concurrentielle et \u00e0 une surveillance automatis\u00e9e sur le march\u00e9 europ\u00e9en des march\u00e9s publics de 2 000 milliards d'euros.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contexte d&#039;autorit\u00e9 et d&#039;approvisionnement<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le Mid South Essex NHS Foundation Trust est class\u00e9 dans l&#039;avis comme un minist\u00e8re ou une autre autorit\u00e9 nationale ou f\u00e9d\u00e9rale, son activit\u00e9 principale \u00e9tant indiqu\u00e9e comme inconnue. Les coordonn\u00e9es renvoient \u00e0 customercare@htepg.com, ce qui indique que la proc\u00e9dure d&#039;achat est g\u00e9r\u00e9e par un prestataire externe et non directement par le Trust. Le num\u00e9ro de t\u00e9l\u00e9phone 01268 524900 correspond \u00e0 la r\u00e9gion d&#039;Essex.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;empreinte d&#039;approvisionnement d&#039;Hermix pour cet acheteur est la suivante\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>78 contrats attribu\u00e9s dans toutes les cat\u00e9gories, pour un montant total de 1,8 milliard d&#039;euros<\/li>\n\n\n\n<li>5 renouvellements toutes cat\u00e9gories confondues, pour un montant total de 838 millions d&#039;euros, dont 4 sont des renouvellements similaires d&#039;une valeur de 690 millions d&#039;euros.<\/li>\n\n\n\n<li>Aucun contrat similaire n&#039;a \u00e9t\u00e9 attribu\u00e9 dans la base de donn\u00e9es Hermix pour cet acheteur sp\u00e9cifique, ce qui signifie qu&#039;aucun contrat ant\u00e9rieur de cette cat\u00e9gorie n&#039;est enregistr\u00e9 sous cette autorit\u00e9.<\/li>\n\n\n\n<li>1 appel d&#039;offres actuellement ouvert, toutes cat\u00e9gories confondues, d&#039;une valeur de 148 millions d&#039;euros (il s&#039;agit du seul appel d&#039;offres ouvert ; les donn\u00e9es contextuelles indiquent 0 appel d&#039;offres ouvert similaire, ce qui sugg\u00e8re que le chiffre de 148 millions d&#039;euros se rapporte \u00e0 une cat\u00e9gorie diff\u00e9rente).<\/li>\n\n\n\n<li>Quinze avis pr\u00e9alables similaires totalisant 3,2 milliards d&#039;euros, ainsi que 38 avis pr\u00e9alables totalisant 4 milliards d&#039;euros, les deux PIN de 2025 font partie de ce record<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Le contexte de march\u00e9 plus large r\u00e9v\u00e8le 765 autres acheteurs ayant des projets similaires, repr\u00e9sentant une valeur totale de 262 milliards d&#039;euros. Ceci t\u00e9moigne de l&#039;importance de la fabrication aseptique et de l&#039;approvisionnement en SACT au sein du NHS et des syst\u00e8mes de sant\u00e9 europ\u00e9ens, m\u00eame si cet acheteur sp\u00e9cifique ne figure pas dans les donn\u00e9es de Hermix concernant d&#039;\u00e9ventuels contrats similaires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les deux avis d&#039;information pr\u00e9alable publi\u00e9s en mai et ao\u00fbt 2025 rev\u00eatent une importance strat\u00e9gique. Le premier avis, paru en mai 2025, \u00e9tait sans valeur. Le second, publi\u00e9 en ao\u00fbt 2025, indiquait une valeur de 789\u00a0239\u00a0286,08\u00a0\u20ac. L&#039;avis de march\u00e9 publi\u00e9 en avril 2026 affiche un montant estim\u00e9 plus \u00e9lev\u00e9, de 1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac. Cette augmentation d&#039;environ 214 millions d&#039;euros entre le second avis et l&#039;avis de march\u00e9 refl\u00e8te probablement des ajustements de p\u00e9rim\u00e8tre ou l&#039;int\u00e9gration de prestations suppl\u00e9mentaires durant la p\u00e9riode de consultation du march\u00e9.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Paysage concurrentiel<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;ensemble de donn\u00e9es Hermix ne fait \u00e9tat d&#039;aucun contrat similaire attribu\u00e9 \u00e0 cet acheteur. Aucun tableau des laur\u00e9ats de contrats similaires n&#039;est disponible dans le PDF publi\u00e9. Ceci est coh\u00e9rent avec les donn\u00e9es contextuelles, qui n&#039;enregistrent aucun contrat similaire d&#039;une valeur de 0 \u20ac pour ce pouvoir adjudicateur. L&#039;absence d&#039;un tableau des contrats historiques emp\u00eache les soumissionnaires de s&#039;appuyer sur des donn\u00e9es ant\u00e9rieures au niveau de l&#039;acheteur pour \u00e9valuer leur position concurrentielle ou leurs prix par rapport \u00e0 leurs fournisseurs pr\u00e9c\u00e9dents.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les donn\u00e9es confirment l&#039;ampleur du march\u00e9 plus vaste des \u00e9quipements de conditionnement d&#039;urgence (SACT) et des m\u00e9dicaments aseptiques. Hermix recense 765 autres acheteurs ayant des projets similaires d&#039;une valeur de 262 milliards d&#039;euros, et cet acheteur a enregistr\u00e9 15 avis d&#039;appel d&#039;offres similaires pour un montant total de 3,2 milliards d&#039;euros. Les 4 renouvellements similaires, d&#039;une valeur de 690 millions d&#039;euros, pr\u00e9sents dans l&#039;ensemble de donn\u00e9es indiquent \u00e9galement que des contrats comparables dans ce secteur sont r\u00e9guli\u00e8rement renouvel\u00e9s au sein du NHS. Ce flux constant de contrats renouvelables est un indicateur direct des opportunit\u00e9s commerciales \u00e0 long terme pour les fournisseurs aseptiques qualifi\u00e9s, au-del\u00e0 de cet appel d&#039;offres sp\u00e9cifique.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En l&#039;absence d&#039;historique de fournisseurs sp\u00e9cifiques \u00e0 l&#039;acheteur, les fournisseurs \u00e9valuant cette opportunit\u00e9 devraient examiner le march\u00e9 plus large des approvisionnements aseptiques en produits oncologiques pour le NHS afin d&#039;identifier les concurrents potentiels. Le march\u00e9 des m\u00e9dicaments oncologiques pr\u00e9par\u00e9s de mani\u00e8re aseptique au Royaume-Uni est un segment sp\u00e9cialis\u00e9 domin\u00e9 par un petit nombre d&#039;unit\u00e9s de fabrication aseptique agr\u00e9\u00e9es, qu&#039;il s&#039;agisse d&#039;unit\u00e9s internes du NHS ou de fabricants de sp\u00e9cialit\u00e9s pharmaceutiques agr\u00e9\u00e9s par la MHRA. La structure des lots (doses par palier, sp\u00e9cifiques au patient, CIVAS, gestion des stocks) correspond directement aux services standard propos\u00e9s par les services aseptiques du NHS et les fabricants sous contrat commerciaux \u00e9tablis dans ce domaine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Signaux commerciaux et proc\u00e9duraux<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Crit\u00e8res d&#039;attribution.<\/strong> Les quatre lots utilisent une pond\u00e9ration identique\u00a0: Technique (incluant la valeur sociale) 65%, Co\u00fbt 35%. La pond\u00e9ration \u00ab\u00a0qualit\u00e9\u00a0\u00bb du lot 65% est \u00e9lev\u00e9e pour un contrat d\u2019approvisionnement pharmaceutique, ce qui indique que l\u2019acheteur accorde une importance consid\u00e9rable aux comp\u00e9tences techniques, \u00e0 la conformit\u00e9 r\u00e9glementaire et \u00e0 l\u2019impact social, en plus du prix. Les soumissionnaires devraient investir de mani\u00e8re significative dans la qualit\u00e9 de leur r\u00e9ponse, notamment en ce qui concerne la conformit\u00e9 aux BPF, les capacit\u00e9s de production aseptique, les syst\u00e8mes de gestion de la qualit\u00e9 et la cr\u00e9ation de valeur sociale.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Proc\u00e9dure. <\/strong>La proc\u00e9dure d&#039;achat est ouverte. Tout fournisseur qualifi\u00e9 peut soumettre une offre sans \u00e9tape de pr\u00e9qualification. Compte tenu de la complexit\u00e9 r\u00e9glementaire de la fabrication aseptique et de la pharmacie oncologique, le crit\u00e8re de qualification est d\u00e9fini par les exigences techniques du dossier d&#039;appel d&#039;offres complet plut\u00f4t que par la proc\u00e9dure elle-m\u00eame.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Couverture g\u00e9ographique.<\/strong> Les quatre lots pr\u00e9cisent le m\u00eame lieu d&#039;ex\u00e9cution\u00a0: le Sud-Est de l&#039;Angleterre, les Midlands de l&#039;Est et les Midlands de l&#039;Ouest. Cette contrainte g\u00e9ographique est significative, puisqu&#039;elle couvre les sites du NHS sur une vaste zone du centre et du sud de l&#039;Angleterre. Les fournisseurs ne disposant pas d&#039;infrastructures de distribution et de cha\u00eene du froid dans ces trois r\u00e9gions devront aborder explicitement leurs capacit\u00e9s logistiques dans leur offre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dur\u00e9e du contrat. <\/strong>La dur\u00e9e de 96 mois (8 ans) est longue pour un accord-cadre d&#039;approvisionnement pharmaceutique. Cela t\u00e9moigne d&#039;une pr\u00e9f\u00e9rence pour la s\u00e9curit\u00e9 d&#039;approvisionnement et la continuit\u00e9 des relations plut\u00f4t que pour les fluctuations concurrentielles \u00e0 court terme. Un contrat de 8 ans dans le secteur des technologies de l&#039;information et de la communication (TIC) exige des fabricants qu&#039;ils d\u00e9montrent une capacit\u00e9 de production stable, une conformit\u00e9 r\u00e9glementaire et une stabilit\u00e9 des prix sur toute la dur\u00e9e du contrat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>P\u00e9riode de soumission.<\/strong> Du 13 avril 2026 (publication) au 11 mai 2026 (date limite), les soumissionnaires disposent de 28 jours calendaires. L&#039;ouverture des plis aura \u00e9galement lieu le 11 mai 2026. Pour un accord-cadre d&#039;approvisionnement pharmaceutique aseptique de cette envergure et d&#039;une telle complexit\u00e9 technique, ce d\u00e9lai de 28 jours est extr\u00eamement court. Les fournisseurs n&#039;ayant pas anticip\u00e9 la p\u00e9riode d&#039;engagement PIN de 2025 auront beaucoup de mal \u00e0 \u00e9laborer une offre conforme et comp\u00e9titive dans ce d\u00e9lai imparti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Valeurs des lots partag\u00e9s. <\/strong>Les quatre lots ont tous la m\u00eame valeur estim\u00e9e de 1\u00a0003\u00a0992\u00a0346,03\u00a0\u20ac. Il s&#039;agit du montant total du cadre, et non d&#039;une valeur individuelle pour chaque lot. Les ench\u00e9risseurs ne doivent pas interpr\u00e9ter ce montant comme signifiant que le cadre vaut quatre fois le montant indiqu\u00e9.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contexte strat\u00e9gique et interpr\u00e9tation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le calendrier de la proc\u00e9dure d&#039;acquisition est d\u00e9lib\u00e9r\u00e9. Le premier avis d&#039;information pr\u00e9alable a \u00e9t\u00e9 publi\u00e9 en mai 2025, soit pr\u00e8s d&#039;un an avant la date limite de d\u00e9p\u00f4t des offres. Un second avis a suivi en ao\u00fbt 2025, cette fois-ci avec une indication de valeur. L&#039;avis de march\u00e9 est paru en avril 2026. Cette p\u00e9riode de consultation \u00e9tendue, s&#039;\u00e9talant sur pr\u00e8s de 12 mois entre le premier avis d&#039;information pr\u00e9alable et la date limite de soumission, est caract\u00e9ristique des march\u00e9s-cadres du NHS (National Health Service) portant sur des biens de grande valeur et techniquement complexes, o\u00f9 l&#039;acheteur souhaite s&#039;assurer que le march\u00e9 est suffisamment pr\u00e9par\u00e9 avant de recevoir les offres.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;augmentation de la valeur, passant de 789 millions d&#039;euros (avis d&#039;appel d&#039;offres d&#039;ao\u00fbt 2025) \u00e0 1\u00a0004 millions d&#039;euros (avis de march\u00e9 d&#039;avril 2026), est \u00e0 noter. Cette hausse de 214 millions d&#039;euros pourrait refl\u00e9ter un \u00e9largissement du p\u00e9rim\u00e8tre des quatre lots, une r\u00e9vision des estimations de volume ou la formalisation de la dur\u00e9e totale du contrat (96 mois) dans le montant total estim\u00e9. Les fournisseurs ayant particip\u00e9 \u00e0 l&#039;appel d&#039;offres de 2025 ont suivi ces \u00e9volutions et affin\u00e9 leurs positions commerciales et techniques au cours des mois suivants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La r\u00e9partition g\u00e9ographique des prestations (Sud-Est, Midlands de l&#039;Est, Midlands de l&#039;Ouest) en fait un cadre infranational mais multi-\u00e9tablissements. Le Mid South Essex NHS Foundation Trust semble agir en tant qu&#039;autorit\u00e9 contractante principale, potentiellement pour le compte de plusieurs \u00e9tablissements du NHS r\u00e9partis sur l&#039;ensemble du territoire concern\u00e9. Le domaine de contact htepg.com sugg\u00e8re que la proc\u00e9dure d&#039;achat est g\u00e9r\u00e9e par un organisme sp\u00e9cialis\u00e9 dans les achats ou les appels d&#039;offres de m\u00e9dicaments du NHS, ce qui correspond \u00e0 la complexit\u00e9 des contrats relatifs aux m\u00e9dicaments SACT.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les utilisateurs d&#039;Hermix qui analysent cet appel d&#039;offres peuvent acc\u00e9der instantan\u00e9ment \u00e0 ces informations concurrentielles, notamment aux profils d\u00e9taill\u00e9s des contractants, aux tendances de d\u00e9penses des autorit\u00e9s et \u00e0 l&#039;ensemble du processus de renouvellement, en quelques minutes plut\u00f4t qu&#039;en quelques heures.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Points cl\u00e9s pratiques pour les soumissionnaires<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">\u00c0 qui s&#039;adresse ce march\u00e9\u00a0:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Unit\u00e9s de fabrication aseptique agr\u00e9\u00e9es par la MHRA, qu&#039;elles soient internes au NHS ou sous contrat avec des entreprises commerciales, disposant d&#039;une accr\u00e9ditation BPF en vigueur et d&#039;une capacit\u00e9 de production adapt\u00e9e aux doses sp\u00e9cifiques et aux patients.<\/li>\n\n\n\n<li>Soci\u00e9t\u00e9s pharmaceutiques sp\u00e9cialis\u00e9es en oncologie et en services aseptiques, entretenant des relations d&#039;approvisionnement \u00e9tablies avec le NHS et disposant de l&#039;agr\u00e9ment r\u00e9glementaire pour fournir des pr\u00e9parations non autoris\u00e9es ou des produits pr\u00e9par\u00e9s de mani\u00e8re aseptique autoris\u00e9s.<\/li>\n\n\n\n<li>Fournisseurs disposant de capacit\u00e9s logistiques et de distribution en cha\u00eene du froid couvrant le Sud-Est, les Midlands de l&#039;Est et les Midlands de l&#039;Ouest de l&#039;Angleterre, capables de livrer le lendemain ou \u00e0 une date pr\u00e9cise \u00e0 de nombreux sites du NHS.<\/li>\n\n\n\n<li>Les organisations capables de d\u00e9montrer une offre de valeur sociale cr\u00e9dible parall\u00e8lement \u00e0 leurs comp\u00e9tences techniques, compte tenu de la pond\u00e9ration de qualit\u00e9 65% qui inclut explicitement la valeur sociale dans les crit\u00e8res d&#039;\u00e9valuation<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Points d'attention critiques :<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>La date limite de soumission est le 11 mai 2026, soit seulement 28 jours calendaires \u00e0 compter de la publication. L&#039;ouverture des plis aura \u00e9galement lieu le 11 mai 2026. Mobilisez imm\u00e9diatement votre \u00e9quipe de soumission\u00a0; les fournisseurs n&#039;ayant pas pr\u00e9par\u00e9 leur candidature suite aux engagements PIN de 2025 seront fortement d\u00e9savantag\u00e9s.<\/li>\n\n\n\n<li>La pond\u00e9ration des crit\u00e8res d&#039;attribution est la suivante\u00a0: Technique (y compris la valeur sociale) 65%, Co\u00fbt 35% pour l&#039;ensemble des quatre lots. Investissez la majeure partie des ressources de l&#039;offre dans la qualit\u00e9 de la r\u00e9ponse, et non dans la mod\u00e9lisation des prix.<\/li>\n\n\n\n<li>Les quatre valeurs de lots indiqu\u00e9es (1\u00a0003\u00a0992\u00a0346,03 \u20ac chacune) correspondent au total du cadre commun, et non \u00e0 des valeurs individuelles. La valeur totale du cadre est d&#039;environ 1 milliard d&#039;euros, et non de 4 milliards d&#039;euros.<\/li>\n\n\n\n<li>Le lieu d&#039;ex\u00e9cution couvre trois r\u00e9gions anglaises. Veuillez d\u00e9montrer explicitement dans votre dossier la distribution et la couverture de la cha\u00eene du froid dans le Sud-Est, les Midlands de l&#039;Est et les Midlands de l&#039;Ouest de l&#039;Angleterre.<\/li>\n\n\n\n<li>La dur\u00e9e de 96 mois exige des preuves cr\u00e9dibles de capacit\u00e9 de production \u00e0 long terme, de m\u00e9canismes de prix stables et de conformit\u00e9 r\u00e9glementaire sur un horizon de 8 ans.<\/li>\n\n\n\n<li>Veuillez consulter les deux avis d&#039;information pr\u00e9alable de 2025 (ukfts_024556-2025 et ukfts_048018-2025) afin de prendre connaissance des \u00e9ventuelles exigences de consultation du march\u00e9 ou des \u00e9tapes de pr\u00e9qualification qui auraient pu pr\u00e9c\u00e9der l&#039;appel d&#039;offres formel.<\/li>\n<\/ul>\n\n\n\n\n\n\n<h2 class=\"wp-block-heading\">Cl\u00f4ture<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ce march\u00e9 se situe \u00e0 la crois\u00e9e des chemins entre la pharmacie oncologique, la cha\u00eene d&#039;approvisionnement du NHS et la fabrication aseptique, un segment sp\u00e9cialis\u00e9 o\u00f9 le respect des r\u00e9glementations, la capacit\u00e9 de production et la s\u00e9curit\u00e9 d&#039;approvisionnement sont aussi importants que le prix. La dur\u00e9e de 96 mois et la pond\u00e9ration de qualit\u00e9 65% t\u00e9moignent d&#039;un acheteur qui privil\u00e9gie la fiabilit\u00e9 \u00e0 la minimisation des co\u00fbts. Pour les fournisseurs aseptiques qualifi\u00e9s de SACT, le d\u00e9lai prolong\u00e9 pour l&#039;obtention du num\u00e9ro PIN signifie que la p\u00e9riode de pr\u00e9paration est ouverte depuis pr\u00e8s d&#039;un an. Le d\u00e9lai de soumission de 28 jours \u00e0 compter de la publication de l&#039;avis de march\u00e9 signifie que cette p\u00e9riode touche \u00e0 sa fin.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cr\u00e9ez votre compte gratuit d\u00e8s aujourd'hui <a href=\"https:\/\/hermix.com\/fr\/sinscrire\/\">https:\/\/hermix.com\/sign-up\/<\/a> et remportez plus de march\u00e9s publics gr\u00e2ce \u00e0 l'approche ax\u00e9e sur les donn\u00e9es qui aide les entreprises \u00e0 r\u00e9ussir syst\u00e9matiquement dans les ventes B2G \u00e0 travers l'Europe.<\/p>\n\n\n<figure class=\"wp-block-post-featured-image\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Appel d&#039;offres public du Mid South Essex NHS Foundation Trust pour des m\u00e9dicaments anticanc\u00e9reux syst\u00e9miques pr\u00e9par\u00e9s de mani\u00e8re aseptique\" style=\"object-fit:cover;\" srcset=\"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png 1200w, https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1-300x157.png 300w, https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1-1024x536.png 1024w, https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1-768x402.png 768w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/><\/figure>","protected":false},"excerpt":{"rendered":"<p>View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":7870,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_angie_page":false,"content-type":"","inline_featured_image":false,"page_builder":"","footnotes":""},"categories":[35],"tags":[],"ppma_author":[17],"class_list":["post-7680","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tender-analysis"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Andreea Ilie\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Hermix - Win Public Contracts with the Power of AI\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix\" \/>\n\t\t<meta property=\"og:description\" content=\"View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-05-18T13:52:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-05-18T13:52:00+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/hermixapp\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@Hermix_sw\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix\" \/>\n\t\t<meta name=\"twitter:description\" content=\"View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@Hermix_sw\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#blogposting\",\"name\":\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix\",\"headline\":\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines\",\"author\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/author\\\/andreea-ilie\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/hermix.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png\",\"width\":1200,\"height\":628,\"caption\":\"Mid South Essex NHS Foundation-Trust public tender-for aseptically prepared systemic anti-cancer therapy medicines\"},\"datePublished\":\"2026-05-18T15:52:00+03:00\",\"dateModified\":\"2026-05-18T15:52:00+03:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#webpage\"},\"articleSection\":\"Tender Analysis, Andreea Ilie\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hermix.com\\\/fr\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/category\\\/tender-analysis\\\/#listItem\",\"name\":\"Tender Analysis\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/category\\\/tender-analysis\\\/#listItem\",\"position\":2,\"name\":\"Tender Analysis\",\"item\":\"https:\\\/\\\/hermix.com\\\/fr\\\/category\\\/tender-analysis\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#listItem\",\"name\":\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#listItem\",\"position\":3,\"name\":\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/category\\\/tender-analysis\\\/#listItem\",\"name\":\"Tender Analysis\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/#organization\",\"name\":\"Hermix\",\"description\":\"Win Public Contracts with the Power of AI\",\"url\":\"https:\\\/\\\/hermix.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.hermix.com\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/hermix_logo.png\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/hermixapp\",\"https:\\\/\\\/twitter.com\\\/Hermix_sw\",\"https:\\\/\\\/www.instagram.com\\\/hermix_sw\\\/\",\"https:\\\/\\\/be.linkedin.com\\\/company\\\/hermix\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/author\\\/andreea-ilie\\\/#author\",\"url\":\"https:\\\/\\\/hermix.com\\\/fr\\\/author\\\/andreea-ilie\\\/\",\"name\":\"Andreea Ilie\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#webpage\",\"url\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/\",\"name\":\"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix\",\"description\":\"View full tender data: https:\\\/\\\/app.hermix.com\\\/opportunities\\\/ukfts_033144-2026 A framework agreement worth just over \\u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/author\\\/andreea-ilie\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/author\\\/andreea-ilie\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/hermix.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#mainImage\",\"width\":1200,\"height\":628,\"caption\":\"Mid South Essex NHS Foundation-Trust public tender-for aseptically prepared systemic anti-cancer therapy medicines\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\\\/#mainImage\"},\"datePublished\":\"2026-05-18T15:52:00+03:00\",\"dateModified\":\"2026-05-18T15:52:00+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/hermix.com\\\/fr\\\/\",\"name\":\"Hermix\",\"description\":\"Win Public Contracts with the Power of AI\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/hermix.com\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Appel d&#039;offres public du Mid South Essex NHS Foundation Trust pour des m\u00e9dicaments anticanc\u00e9reux syst\u00e9miques pr\u00e9par\u00e9s de mani\u00e8re aseptique - Hermix","description":"Consultez l&#039;int\u00e9gralit\u00e9 des donn\u00e9es de l&#039;appel d&#039;offres\u00a0: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026. Un accord-cadre d&#039;une valeur d&#039;un peu plus d&#039;un milliard de livres sterling sur 96 mois porte sur les m\u00e9dicaments anticanc\u00e9reux \u00e0 doses variables, personnalis\u00e9s et CIVAS, ainsi que sur les services de gestion des stocks. Cet accord est structur\u00e9 pour desservir les \u00e9tablissements du NHS dans le sud-est, les Midlands de l&#039;Est et les Midlands de l&#039;Ouest de l&#039;Angleterre. Le Mid South Essex NHS Foundation Trust a publi\u00e9 un avis de march\u00e9.","canonical_url":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#blogposting","name":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix","headline":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines","author":{"@id":"https:\/\/hermix.com\/fr\/author\/andreea-ilie\/#author"},"publisher":{"@id":"https:\/\/hermix.com\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png","width":1200,"height":628,"caption":"Mid South Essex NHS Foundation-Trust public tender-for aseptically prepared systemic anti-cancer therapy medicines"},"datePublished":"2026-05-18T15:52:00+03:00","dateModified":"2026-05-18T15:52:00+03:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#webpage"},"isPartOf":{"@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#webpage"},"articleSection":"Tender Analysis, Andreea Ilie"},{"@type":"BreadcrumbList","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr#listItem","position":1,"name":"Home","item":"https:\/\/hermix.com\/fr","nextItem":{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr\/category\/tender-analysis\/#listItem","name":"Tender Analysis"}},{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr\/category\/tender-analysis\/#listItem","position":2,"name":"Tender Analysis","item":"https:\/\/hermix.com\/fr\/category\/tender-analysis\/","nextItem":{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#listItem","name":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines"},"previousItem":{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#listItem","position":3,"name":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines","previousItem":{"@type":"ListItem","@id":"https:\/\/hermix.com\/fr\/category\/tender-analysis\/#listItem","name":"Tender Analysis"}}]},{"@type":"Organization","@id":"https:\/\/hermix.com\/fr\/#organization","name":"Hermix","description":"Win Public Contracts with the Power of AI","url":"https:\/\/hermix.com\/fr\/","logo":{"@type":"ImageObject","url":"https:\/\/www.hermix.com\/wp-content\/uploads\/2022\/04\/hermix_logo.png","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#organizationLogo"},"image":{"@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/hermixapp","https:\/\/twitter.com\/Hermix_sw","https:\/\/www.instagram.com\/hermix_sw\/","https:\/\/be.linkedin.com\/company\/hermix"]},{"@type":"Person","@id":"https:\/\/hermix.com\/fr\/author\/andreea-ilie\/#author","url":"https:\/\/hermix.com\/fr\/author\/andreea-ilie\/","name":"Andreea Ilie"},{"@type":"WebPage","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#webpage","url":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/","name":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix","description":"View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/hermix.com\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#breadcrumblist"},"author":{"@id":"https:\/\/hermix.com\/fr\/author\/andreea-ilie\/#author"},"creator":{"@id":"https:\/\/hermix.com\/fr\/author\/andreea-ilie\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png","@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#mainImage","width":1200,"height":628,"caption":"Mid South Essex NHS Foundation-Trust public tender-for aseptically prepared systemic anti-cancer therapy medicines"},"primaryImageOfPage":{"@id":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/#mainImage"},"datePublished":"2026-05-18T15:52:00+03:00","dateModified":"2026-05-18T15:52:00+03:00"},{"@type":"WebSite","@id":"https:\/\/hermix.com\/fr\/#website","url":"https:\/\/hermix.com\/fr\/","name":"Hermix","description":"Win Public Contracts with the Power of AI","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/hermix.com\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Hermix - Win Public Contracts with the Power of AI","og:type":"article","og:title":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix","og:description":"View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice","og:url":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/","og:image":"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png","og:image:secure_url":"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png","og:image:width":1200,"og:image:height":628,"article:published_time":"2026-05-18T13:52:00+00:00","article:modified_time":"2026-05-18T13:52:00+00:00","article:publisher":"https:\/\/www.facebook.com\/hermixapp","twitter:card":"summary_large_image","twitter:site":"@Hermix_sw","twitter:title":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines - Hermix","twitter:description":"View full tender data: https:\/\/app.hermix.com\/opportunities\/ukfts_033144-2026 A framework agreement worth just over \u00a31 billion across 96 months covering dose banded, patient specific and CIVAS cancer medicines alongside stock inventory management services, structured to serve NHS sites across South East, East Midlands and West Midlands England. Mid South Essex NHS Foundation Trust has published a contract notice","twitter:creator":"@Hermix_sw","twitter:image":"https:\/\/hermix.com\/wp-content\/uploads\/2026\/05\/Mid-South-Essex-NHS-Foundation-Trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines_featured-image-1.png"},"aioseo_meta_data":{"post_id":"7680","title":null,"description":null,"keywords":null,"keyphrases":{"focus":[],"additional":[]},"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-08-13 01:26:50","updated":"2026-08-20 11:56:21"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/hermix.com\/fr\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/hermix.com\/fr\/category\/tender-analysis\/\" title=\"Tender Analysis\">Tender Analysis<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tMid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/hermix.com\/fr"},{"label":"Tender Analysis","link":"https:\/\/hermix.com\/fr\/category\/tender-analysis\/"},{"label":"Mid South Essex NHS Foundation Trust public tender for aseptically prepared systemic anti-cancer therapy medicines","link":"https:\/\/hermix.com\/fr\/mid-south-essex-nhs-foundation-trust-public-tender-for-aseptically-prepared-systemic-anti-cancer-therapy-medicines\/"}],"authors":[{"term_id":17,"user_id":3,"is_guest":0,"slug":"andreea-ilie","display_name":"Andreea Ilie","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/cb0674b58c82c13f3140f57ce6b238abab5257f06d482468c588e76c72b29e8c?s=96&d=mm&r=g","author_category":"","first_name":"","last_name":"","user_url":"","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/posts\/7680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/comments?post=7680"}],"version-history":[{"count":0,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/posts\/7680\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/media\/7870"}],"wp:attachment":[{"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/media?parent=7680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/categories?post=7680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/tags?post=7680"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/hermix.com\/fr\/wp-json\/wp\/v2\/ppma_author?post=7680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}